Carbinoxamine Maleate is a well-known allergy medication dating back to the 1950s, and FSC Pediatrics, in collaboration with Tris Pharmaceuticals, licensed Karbinal ER (extended release)–a re-formulation for pediatrics. These companies tasked Brandsymbol with crafting a comprehensive brand launch program for the then-unreleased drug. Our team delivered the messaging and positioning “What is your next level of symptomatic relief,” spoke to the trust behind Carbinoxamine Maleate, as well as the innovation this new product offered. We also created a striking visual identity featuring a bridge with a child crossing. This identity provides customers with a clear story that has resulted in commercial success for the product since launching.